Gregg Gilbert
Stock Analyst at Truist Securities
(2.29)
# 2,584
Out of 4,876 analysts
91
Total ratings
53.7%
Success rate
5.38%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $11.03 | +54.13% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $29.95 | +23.54% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $46.36 | +81.21% | 9 | Sep 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Buy | $430 → $525 | $775.28 | -32.28% | 10 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $9.14 | +42.31% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $18.02 | - | 10 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $93 | $79.06 | +17.63% | 8 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $13.75 | +249.09% | 2 | Feb 2, 2021 | |
| CHRS Coherus Oncology | Initiates: Buy | $26 | $0.74 | +3,398.86% | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $0.93 | +16,034.24% | 1 | Jan 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $26.51 | +194.23% | 17 | Aug 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $156.17 | -50.05% | 5 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $16.75 | +7.46% | 6 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $113.99 | - | 7 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $106.94 | +63.64% | 6 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $182.32 | -63.80% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $11.03
Upside: +54.13%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $29.95
Upside: +23.54%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $46.36
Upside: +81.21%
Eli Lilly and Company
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $775.28
Upside: -32.28%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $9.14
Upside: +42.31%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $18.02
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $79.06
Upside: +17.63%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $13.75
Upside: +249.09%
Coherus Oncology
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $0.74
Upside: +3,398.86%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $0.93
Upside: +16,034.24%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $26.51
Upside: +194.23%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $156.17
Upside: -50.05%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $16.75
Upside: +7.46%
Nov 20, 2017
Downgrades: Sell
Price Target: n/a
Current: $113.99
Upside: -
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $106.94
Upside: +63.64%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $182.32
Upside: -63.80%